大型医用设备成本效益分析在HIS上的实现

介绍了大型医疗设备成本效益分析应用系统挂接HIS(“军字一号”)上的设计、功能实现及应用。该应用系统部分实现了大型医用设备的现代经济管理。     

Failure of intensive chemotherapy in poor prognosis non-Hodgkin's lymphoma

In an attempt to improve response and survival rates in patients with non-Hodgkin's lymphoma, a relatively intense six drug regimen MATCOP was developed comprising four-weekly cycles of methotrexate (100mg/m², IV_Y day 8), Adriamycin (30mg/m², IV_Y days 1,2), teniposide (75 mg/rn², IV, day 1), cyclophophamide (300 mg/m², po, days one to five), Oncovin (1.4 mg/m², IV: maximum 2 mg, days 8,15) and prednisolone (100 mg, po, days one to five). A randomised trial was conducted comparing MATCOP with the standard CHOP regimen, comprising three-weekly cycles of cyclophosphamide (750 mg/m², IV, day 1), Adriamycin (50 mg/m², IV, day 1), Oncovin (1.4 mg/m² IV: maximum 2 mg, day 1) and prednisolone (100 mg, PO, days two to six). Eighty patients with large cell lymphoma, diffuse mixed small cleaved and large cell lymphoma or diffuse small cleaved cell lymphoma were randomised, 47 to MATCOP and 33 to CHOP. MATCOP patients experienced increased granulocytopenia, thrombocytopenia (p 0.0001), mucositis (p= 0.002) and infections (p= 0.01) compared to CHOP patients. Complete response rates were similar: 66% for MATCOP patients and 61% for CHOP patients. There were no apparent differences in the time to relapse for patients achieving CR, the time to treatment failure or the overall survival time. Thus despite an increase in toxicity, the more intense regimen MATCOP failed to confer any therapeutic benefit compared with the standard CHOP regimen. Survival was not influenced but toxicity was increased by dose intensification. (Aust NZ J Med 1992; 22: 123–128.)     

对LASIK手术中游离瓣的处理

目的 探讨LASIK手术中出现游离瓣的原因及处理方法。方法 对1500例（2900眼）LASIK手术中出现的9例（9眼）游离瓣进行随访观察。结果 术后1天，9例（9眼）角膜瓣复位良好，边缘整齐，瓣下干净。术后3天取出角膜接触镜，其中7眼视力≥1．0，2眼视力≥0．6。1月视力均达到最佳矫正视力，6月～1年视力稳定。结论LASIK手术中出现游离瓣只要及时正确处理，仍能获得最佳矫正视力。     

HIV-1膜抗原部分糖基化位点改造对免疫原性及假病毒形成的影响

目的 研究HIV-1膜蛋白(Env)特定糖基化位点改造对Env免疫原性及功能性假病毒形成能力的影响.方法 采用环形诱变,DpnⅠ筛选的方法对Env进行定点突变,单周期感染试验检测功能性假病毒形成能力,免疫小鼠,利用假病毒中和试验与ELISPOT分别检测突变对中和抗体和T细胞分泌Env特异的IFN-γ的影响.结果 N197Q突变体使Env诱导中和抗体的能力提高而诱导T细胞分泌Env特异的IFN-γ的能力降低,并使Env不能形成功能性假病毒;G2突变体(N624Q,N637Q)诱导的中和抗体能更好地中和假病毒74-2,仉中和假病毒Wt的能力下降,对Env诱导T细胞分泌Env特异的IFN-γ的能力和功能性假病毒形成无明显影响.结论 特定糖基化位点的改造影响假病毒的形成及Env的免疫原性.     

带蒂皮瓣修复关节损伤的实验研究

目的：将家兔带蒂皮瓣移植于破坏掉关节软骨的股骨头上,探讨皮肤成纤维细胞的成软骨潜能。方法：用家兔２０只,每只任选一侧股骨头作为实验组,对侧作为对照组。将带蒂皮瓣移植于破坏掉了关节软骨的股骨头上后,将股骨头复位,作为实验组。对侧则以游离全厚皮片作对照。分别在术后８ｗｋ、１６ｗｋ时各探查１０只动物,通过肉眼观察,光镜观察移植物的转归。结果：实验组皮瓣成活并以骨头愈合,表皮逐渐变性消失,真皮纤维组织增生     

医学声像示教实时双向同步传输系统的研制

研制开发病房大楼手术摄像、内窥镜、电子显微镜、病理图像等医学声像信号与科教（培训交流）中心、阶梯教室、示教室、主任办公室等终端医学声像信号的实时双向同步传输示教系统，以弥补PACS系统单向、帧传、滞后的缺陷．为大型学术交流、现场教学示教观摩提供技术支持。     

Mortality within 30 days of receiving systemic anti‐cancer therapy at a regional oncology unit: What have we learned?

Aims: Benefits to patients from systemic anti‐cancer therapies (SACT) occur at a cost of significant toxicities that can be life threatening. Published data of SACT mortality outside clinical trials is limited with no published Australia data. We aim to establish local outcomes at a regional Victorian oncology center to allow comparison with limited international data. Methods: An audit was undertaken at Ballarat Health Services to analyze all deaths occurring within 30 and 60 days of receiving SACT (cytotoxic chemotherapy and targeted therapy) for epithelial malignancies and hematological malignancies (excluding acute leukemia), over a 12‐month period. Hormonal therapy was excluded. Results: Between 1 January and 31 December 2008, 378 patients received SACT. In total 13 deaths (3.4%) occurred within 30 days following SACT. Three deaths (23%) were definitely treatment‐related – neutropenic sepsis, pneumocystis pneumonia and bowel perforation, respectively. Eight deaths (62%) were definitely unrelated to treatment. Most deaths were due to disease progression (six patients) For two patients (15%), the cause of death was unknown. Most patients were treated with palliative intent. Most patients were receiving first‐line treatment (seven patients, 50%). A further five deaths (1.3%) occurred 31–60 days after SACT, four of which were due to disease progression. Conclusion: Our local outcome data are comparable to limited current international data. This type of audit reviews local outcomes and identifies factors contributing to mortality in order to improve standards of care. We encourage similar audits to establish national benchmarks of 30‐day mortality rate.